To determine whether inhibition of the Ras/MAPK or PI3K/AKT pathways could rescue the skeletal myopathy caused by the HrasG12V mutation in vivo, either MEKi PD0325901 or PI3Ki GDC0941 was administered daily to 3-month-old adult HrasG12V and WT mice for 28 days. This evidence concerns the gene AKT1 and skeletal muscle disorder.